Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 85
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Infect Chemother ; 28(3): 384-388, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-34823994

RESUMO

INTRODUCTION: Children with severe motor and intellectual disabilities (SMID) are susceptible to severe lower respiratory tract infection (LTRI). As SMID patients are prone to develop recurrent wheezing and are often diagnosed with bronchial asthma, they frequently receive systemic corticosteroids as an adjunctive treatment for LRTIs. However, the efficacy of corticosteroid therapy for LTRIs in SMID children is unclear. We investigated whether or not corticosteroid therapy was associated with better clinical outcomes for SMID children with LRTIs. METHODS: Our retrospective study enrolled 217 SMID children 1-15 years old hospitalized for LTRIs. We compared the clinical characteristics and outcomes between patients with and without corticosteroid therapy. RESULTS: Of the 217 patients, 29 (13.3%) received corticosteroid therapy. The proportion of patients with a history of bronchial asthma was higher and LRTI was more severe in patients with corticosteroid therapy than in those without the therapy. The length of hospital stay (LOHS) was significantly longer in patients with corticosteroid therapy (median 13 days) than in those without corticosteroid therapy (median 9 days) (P = 0.02). The same tendency was shown for the LOHS in patients with severe or moderate LRTI, although not to a significant extent. CONCLUSION: Systemic corticosteroid therapy was not associated with better clinical outcomes in SMID children with LRTIs, even if the patients suffer from severe LRTIs. Corticosteroids should be used cautiously for LRTIs in SMID children because bronchial asthma is likely to be overdiagnosed in these children.


Assuntos
Deficiência Intelectual , Infecções Respiratórias , Adolescente , Criança , Pré-Escolar , Hospitalização , Humanos , Lactente , Deficiência Intelectual/complicações , Deficiência Intelectual/tratamento farmacológico , Tempo de Internação , Infecções Respiratórias/complicações , Infecções Respiratórias/tratamento farmacológico , Estudos Retrospectivos
2.
Int J Urol ; 29(12): 1543-1550, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36102367

RESUMO

OBJECTIVES: In children with a first Escherichia coli-induced febrile urinary tract infection (fUTI), routine voiding cytourethrography (VCUG) is not recommended for detecting vesicoureteral reflux (VUR). Meanwhile, the sensitivity of renal and bladder ultrasound (RBUS) for detecting VUR is insufficient. Aiming to implement VCUG properly for children with a first E. coli-induced fUTI, we attempted to construct a predictive scoring system for the early screening of VUR. METHODS: This study enrolled patients aged <2 years of age hospitalized for their first E. coli-induced fUTI during the period when VCUG was implemented for all patients (2007-14, non-selective group [n = 111]) and only for those with VUR-suspected RBUS findings, bacteremia or acute focal bacterial nephritis (2016-19, selective group [n = 102]). We evaluated the accuracy of the current criteria and the VUR predictive score constructed using data from the non-selective group. RESULTS: In the non-selective group, 32 patients had VUR (29%). In the selective group, 20 of 45 VCUG-tested patients had VUR (44%). Among 57 patients not undergoing VCUG in the selective group, 8 had a recurrence of fUTI, 3 of whom were diagnosed with VUR. In the non-selective group, 9 patients with VUR did not fulfill the current criteria and the VUR predictive score consisting of young age, female sex, prolonged fever, hypoproteinemia, hyponatremia and hyperglycemia, showed higher sensitivity, specificity than the current criteria. CONCLUSIONS: The current imaging/bacteriological criteria were ineffective in screening for VUR in patients with their first E. coli-induced fUTI. The VUR predictive score can be an accurate indicator for implementing VCUG.


Assuntos
Infecções por Escherichia coli , Infecções Urinárias , Refluxo Vesicoureteral , Humanos , Criança , Feminino , Lactente , Pré-Escolar , Refluxo Vesicoureteral/diagnóstico , Refluxo Vesicoureteral/diagnóstico por imagem , Escherichia coli , Infecções Urinárias/diagnóstico , Infecções por Escherichia coli/complicações , Infecções por Escherichia coli/diagnóstico , Micção , Estudos Retrospectivos
3.
J Pediatr ; 236: 95-100, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-34019881

RESUMO

OBJECTIVE: To investigate the incidence of coronary artery abnormalities (CAAs) by fever pattern after intravenous immunoglobulin (IVIG) therapy in patients with Kawasaki disease. STUDY DESIGN: This retrospective cohort study included 172 patients with Kawasaki disease aged ≤12 years who underwent IVIG therapy and had no CAAs before treatment. Resistance to initial IVIG was defined as persistent fever ≥37.5 °C for ≥24 hours after therapy or the recurrence of Kawasaki disease after initial defervescence. The patients were divided into 3 groups: IVIG responders, nonresponders with persistent fever, and nonresponders with recurrent fever. CAAs were evaluated 2 or 4 weeks and 12 months after onset and were defined by a coronary artery z-score ≥2.5. RESULTS: The incidence of CAAs within 12 months after onset was significantly higher in nonresponders with persistent fever (27%) compared with the other 2 groups. On multivariate logistic regression analysis, being a nonresponder with persistent fever was an independent risk factor for having CAAs within 12 months after the onset of Kawasaki disease (OR, 6.48; P = .007). CONCLUSIONS: In patients with Kawasaki disease resistant to IVIG therapy, persistent fever, but not recurrent fever, was found to be a risk factor for the incidence of CAAs. Aggressive additional therapy may be beneficial to prevent CAA formation in patients with Kawasaki disease with persistent fever.


Assuntos
Anomalias dos Vasos Coronários/epidemiologia , Febre/epidemiologia , Imunoglobulinas Intravenosas/uso terapêutico , Fatores Imunológicos/uso terapêutico , Síndrome de Linfonodos Mucocutâneos/tratamento farmacológico , Criança , Pré-Escolar , Anomalias dos Vasos Coronários/diagnóstico , Feminino , Febre/diagnóstico , Humanos , Incidência , Lactente , Masculino , Síndrome de Linfonodos Mucocutâneos/complicações , Estudos Retrospectivos , Fatores de Risco
4.
Eur J Clin Microbiol Infect Dis ; 40(9): 2011-2015, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-33661411

RESUMO

We investigated the recent epidemiology and characteristics of influenza-related hospitalization in Japanese children. This study included 3741 children with influenza. Children hospitalized for febrile seizures (FS) induced by etiologies other than influenza also served as a disease control. Most outpatients (92.8%) visited our hospital with complaints of respiratory symptoms, whereas FS were the most predominant symptoms of inpatients (58/154, 37.7%). Children with influenza-induced FS were significantly older than those with FS induced by other etiologies (P <0.001). Although the characteristics of severe influenza may vary throughout the world, the analysis of influenza-induced neurological disorders is important for understanding its epidemiology.


Assuntos
Hospitalização/estatística & dados numéricos , Influenza Humana/complicações , Infecções Respiratórias/epidemiologia , Convulsões Febris/epidemiologia , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Vírus da Influenza A/genética , Vírus da Influenza A/patogenicidade , Influenza Humana/epidemiologia , Japão , Masculino , Infecções Respiratórias/virologia , Estudos Retrospectivos , Convulsões Febris/etiologia
5.
Pediatr Int ; 63(12): 1466-1471, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33780596

RESUMO

BACKGROUND: Large numbers of patients with diseases preventable by voluntary vaccines have been reported in Japan. However, it is difficult to analyze the impact of voluntary vaccination on disease prevention, as governments do not aggregate the number of recipients of vaccines that are not included in the national immunization program. This study investigated the association between the coverage rates of two voluntary vaccines (rotavirus and mumps vaccines) and the incidence of the diseases preventable by these vaccines. METHODS: We performed a prospective questionnaire-based observational study to investigate the presumptive coverage rates of the rotavirus vaccine in infancy and the mumps vaccine at 1 year of age in Kitakyushu City from 2015 to 2018. The number of children admitted to a secondary medical institution for rotavirus-associated gastroenteritis and the incidence of mumps infection in sentinel medical institutions were also analyzed during the investigation period. RESULTS: The rotavirus and mumps vaccine coverage rates since 2016 were 61-63% and late 28-30%, respectively (52.6% and 20.3% in 2015, respectively). The yearly number of children hospitalized for rotavirus-associated gastroenteritis from 2015 to 2018 declined by 41.4% compared with that during the pre-vaccination period (2009-2011). The incidence of mumps infection remained unchanged during the investigation period. CONCLUSION: The coverage rates of two voluntary vaccines were not high enough to control the infections. The incorporation of voluntary vaccines into the routine immunization program should be considered as the one of the effective ways to increase vaccination coverage.


Assuntos
Gastroenterite , Infecções por Rotavirus , Vacinas contra Rotavirus , Criança , Humanos , Lactente , Japão/epidemiologia , Estudos Prospectivos , Vacinação , Cobertura Vacinal
6.
J Infect Chemother ; 26(3): 206-210, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-31563335

RESUMO

Rotavirus (RV) vaccine contributed to the reduction of the hospitalization for gastroenteritis (GE)-associated convulsion whereas there were few studies investigating the vaccination rate and the reduction of the disease simultaneously. The aim of this study is to investigate the alterations of the epidemiology and clinical characteristics of RVGE-associated convulsion after the introduction of RV vaccines and evaluate the reduction of the disease in the context of the vaccination rate. This retrospective study included hospitalized patients with GE and GE-associated convulsion from 2009 to 2015. The proportion of patients with RVGE and RVGE-associated convulsion and the clinical characteristics of RVGE-associated convulsion were compared between the pre- (2009-2011) and post-vaccination periods (2013-2015). The presumptive RV vaccination rate in the subject area was also investigated. During the pre- and post-vaccination periods, 47 and 49 patients with GE-associated convulsion, and 319 and 330 with GE were enrolled, respectively. Proportions of both hospitalized patients with RVGE-associated convulsion and those with RVGE during the post-vaccination period were significantly lower than those during the pre-vaccination periods (P = 0.042 and P = 0.003). Serum sodium level was significantly lower in hospitalized patients with RVGE-associated convulsion during the post-vaccination period (P = 0.021). The presumptive RV vaccination rates were 35.9%, 45.8% and 52.6% in 2013, 2014 and 2015, respectively. The proportions of hospitalized patients with RVGE-associated convulsion as well as those with RVGE decreased after the introduction of RV vaccine. RV vaccination would be also effective for the prevention of extra-intestinal complications of the virus.


Assuntos
Gastroenterite , Infecções por Rotavirus , Vacinas contra Rotavirus , Convulsões , Pré-Escolar , Gastroenterite/epidemiologia , Gastroenterite/virologia , Hospitalização/estatística & dados numéricos , Humanos , Lactente , Japão , Estudos Retrospectivos , Infecções por Rotavirus/complicações , Infecções por Rotavirus/epidemiologia , Infecções por Rotavirus/prevenção & controle , Convulsões/epidemiologia , Convulsões/virologia , Vacinação/estatística & dados numéricos
7.
Tohoku J Exp Med ; 250(3): 181-190, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-32213753

RESUMO

Varicella zoster virus (VZV) causes a life-threatening infection in immunocompromised hosts. The immune response to VZV of healthy subjects has been rigorously assessed, but little is known about that of immunocompromised individuals. This study aimed to clarify the primary response to VZV infection in immunocompromised children. This prospective study enrolled six immunocompromised children (median age, 33 months; range, 20-62) receiving steroids or immunosuppressants, and 10 immunocompetent children (median age, 32 months; range, 15-81) with varicella. The immunocompromised children were three patients with acute lymphoblastic leukemia, two recipients with liver transplantation and one patient with juvenile idiopathic arthritis. Interferon-γ-producing CD69+T-cells produced by VZV stimulation (VZV-specific T-cells) were studied during the acute or convalescent phase. To further address the direct effect of immunosuppressants, we analyzed the number of VZV-specific T-cells after stimulating peripheral blood mononuclear cells obtained from healthy adults with live-attenuated VZV with or without prednisolone, cyclosporine-A, or tacrolimus. The circulating numbers of lymphocytes in the convalescent stage but not acute stage were lower in immunocompromised children compared with immunocompetent children. In the acute stage, immunocompromised patients showed lower VZV-specific CD8+T-cell counts than immunocompetent subjects. In contrast, in the convalescent phase, immunocompromised patients had lower VZV-specific CD4+T-cell counts than immunocompetent hosts. The in vitro culture of activated lymphocytes with prednisolone or immunosuppressants significantly decreased the proportion of VZV-specific CD4+T-cells. In conclusion, the decreased numbers of VZV-specific CD8+T-cells during the acute phase and VZV-specific CD4+T-cells during the convalescent phase of disease may account for severe varicella in immunocompromised children.


Assuntos
Varicela/imunologia , Varicela/virologia , Herpesvirus Humano 3/imunologia , Linfócitos T/imunologia , Antígenos CD/metabolismo , Antígenos de Diferenciação de Linfócitos T/metabolismo , Varicela/tratamento farmacológico , Criança , Pré-Escolar , Convalescença , Humanos , Imunocompetência , Imunossupressores/uso terapêutico , Lactente , Interferon gama/metabolismo , Lectinas Tipo C/metabolismo , Ativação Linfocitária/imunologia , Contagem de Linfócitos , Especificidade da Espécie , Doadores de Tecidos
8.
J UOEH ; 42(2): 209-216, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32507844

RESUMO

Ventriculoperitoneal (VP) shunt placement is commonly performed for the treatment of hydrocephalus, and several complications of this procedure are well known. Radiating shoulder tip pain after VP shunt placement has been reported as an unusual complication in a few cases, associated with dislocation of the peritoneal catheter. We described the case of a 9-year-old girl who presented with recurrent radiating shoulder tip pain after VP shunt placement. The pain recurred after peritoneal catheter repositioning because of peritoneal inflammation and adhesion due to peritonitis with Propionibacterium acnes (P. acnes). This bacterium was isolated using 16S ribosomal RNA gene polymerase chain reaction (16S rRNA gene PCR), and anaerobic and prolonged culture tests. After antibacterial treatment, ventriculoarterial (VA) shunt placement was successfully performed. Hemidiaphragm irritation by the peritoneal catheter leads to radiating shoulder tip pain, and peritoneal inflammation and adhesion caused by infectious peritonitis may cause recurrence of this despite catheter repositioning. Clinicians should be aware of shoulder pain as a complication of VP shunt placement, and should consider VA shunt placement as an alternative treatment if this symptom recurs after catheter repositioning. Furthermore, 16S rRNA gene PCR and anaerobic and prolonged culture tests should be considered to detect P. acnes infection.


Assuntos
Dor Pós-Operatória/etiologia , Peritonite/etiologia , Peritonite/microbiologia , Propionibacterium acnes , Recidiva , Derivação Ventriculoperitoneal/efeitos adversos , Feminino , Humanos
9.
Clin Infect Dis ; 68(12): 2099-2104, 2019 05 30.
Artigo em Inglês | MEDLINE | ID: mdl-30252025

RESUMO

BACKGROUND: Japanese encephalitis (JE) is the leading cause of viral encephalitis with high mortality and morbidity in Asia. In Japan, however, the active recommendation of JE vaccine was retracted in 2005 because of the potential risk of acute disseminated encephalomyelitis. We aimed to determine the recent incidence of childhood-onset JE after the domestic change of vaccination policy in Japan, and to analyze the clinical features of affected children. METHODS: A retrospective nationwide survey was conducted for pediatric patients with JE in Japan from 1995 to 2015. The national surveillance system was used to identify the pediatric patients with JE. Follow-up questionnaires were sent to analyze their clinical and neuroimaging profiles. RESULTS: Among a total of 109 patients registered to the national surveillance, 10 (9%) were less than age 15 years. The annual incidence rate of childhood-onset JE was higher during 2005-15 than that during 1995-2004 (4.3 × 10-3 vs 1.1 × 10-3 per 100000, respectively; P = .04). Endemic regions overlapped with prefectures that farmed pigs harboring antibodies against JE virus with high prevalence. Detailed clinical data were collected from 9 patients. None of them died, but 5 of 9 patients (56%) had neurological sequelae after recovery. One patient who was partially vaccinated with 2 doses of JE vaccine fully recovered from a coma. The age of 3 years or less was associated with unfavorable neurological prognosis. CONCLUSIONS: Our data provide evidence for the importance and prophylactic effect of the JE vaccine in young children in the endemic area.


Assuntos
Vírus da Encefalite Japonesa (Subgrupo) , Encefalite Japonesa/epidemiologia , Criança , Pré-Escolar , Encefalite Japonesa/diagnóstico , Encefalite Japonesa/terapia , Encefalite Japonesa/virologia , Feminino , Geografia Médica , Hospitalização , Humanos , Incidência , Lactente , Japão/epidemiologia , Masculino , Neuroimagem , Vigilância em Saúde Pública , Estudos Retrospectivos , Vacinação
10.
Eur J Clin Microbiol Infect Dis ; 38(12): 2365-2369, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31482417

RESUMO

Gentamicin (GM) is used for neonates as the initial treatment for neonatal bacterial infection. An association between high trough GM levels and the elevation of the serum creatinine (sCr) level and hearing loss has been reported, although there have been no reports investigating the serial changes in the sCr level in preterm neonates treated with GM. The present study evaluated the serial changes in the sCr level and the incidence of hearing loss in preterm neonates treated with GM. This study included 56 neonates born at a gestational age of 32-36 weeks. Fifteen (group 1) and 20 (group 2) neonates were treated with 2.5 mg/kg of GM every 12 h and 4 mg/kg of GM every 36 h, respectively. Group 3 included 21 neonates without GM therapy. Serum GM levels, serial changes in the sCr levels, and the incidence of hearing loss were then compared among the three groups. The serum trough GM level in group 2 was significantly lower than that in group 1 (P < 0.001), whereas the serum peak GM levels in these groups were almost the same. The ratio of the sCr level at birth to that at the 5th day of life in group 1 was the lowest among the 3 groups. No neonates had hearing loss. GM therapy worsened the sCr level in late preterm neonates, especially those with multiple doses per day. The appropriate use of GM is needed in order to prevent the occurrence of nephrotoxicity.


Assuntos
Antibacterianos/efeitos adversos , Creatinina/sangue , Gentamicinas/efeitos adversos , Recém-Nascido Prematuro , Antibacterianos/administração & dosagem , Antibacterianos/sangue , Infecções Bacterianas/prevenção & controle , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Gentamicinas/administração & dosagem , Gentamicinas/sangue , Idade Gestacional , Humanos , Recém-Nascido , Unidades de Terapia Intensiva Neonatal , Japão , Masculino
11.
J Infect Chemother ; 25(5): 376-378, 2019 May.
Artigo em Inglês | MEDLINE | ID: mdl-30595347

RESUMO

We report a pediatric case aged 10 years with Granulicatella adiacens-associated chronic mandibular osteomyelitis. The causative pathogen was uncertain because polymicrobial species were detected from the bacterial culture in bone marrow fluid. In contrast, G. adiacens was predominantly identified in the clone library analysis of the bacterial 16S rRNA gene sequence. Vancomycin to which G. adiacens was reported to be susceptible was not administrated sufficiently to this patient because of its adverse event, whereas linezolid and ciprofloxacin was alternatively effective for the treatment of chronic mandibular osteomyelitis.


Assuntos
Antibacterianos/uso terapêutico , Carnobacteriaceae/patogenicidade , Mandíbula/microbiologia , Osteomielite/microbiologia , Carnobacteriaceae/genética , Carnobacteriaceae/isolamento & purificação , Criança , Doença Crônica/terapia , Curetagem , Quimioterapia Combinada , Feminino , Humanos , Oxigenoterapia Hiperbárica , Mandíbula/diagnóstico por imagem , Osteomielite/diagnóstico , Osteomielite/patologia , Osteomielite/terapia , RNA Ribossômico 16S/isolamento & purificação , Tomografia Computadorizada por Raios X , Resultado do Tratamento
14.
J Infect Chemother ; 24(1): 40-44, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29153553

RESUMO

An early switch from intravenous to oral antimicrobial therapy is useful for reducing the duration of the hospitalization in adult patients with community acquired-pneumonia, whereas the efficacy of switch therapy for pediatric patients with community acquired (CA)-lower respiratory tract infection (LRTI) is uncertain. The aim of this study is to investigate the efficacy of switch therapy for LRTI in patients with severe motor intellectual disabilities (SMID). This retrospective study was performed on 92 patients with SMID who were admitted to the Department of Pediatrics at the Hospital of University of Occupational and Environmental Health, Japan from April 1, 2010 to March 31, 2017 for the suspicion of bacterial LRTI and were initially treated with an intravenous antimicrobial agent. Clinical outcomes were compared between patients with switch therapy (Switch therapy group) and conventional intravenous antimicrobial therapy (No switch therapy group). Thirteen and 79 in patients with SMID belonged to Switch thrapy group and No switch therapy group, respectively. Length of hospital stay in Switch therapy group was significantly shorter than that in No switch therapy group (P = 0.002). In the patients undergoing switch therapy, there was no patient who required re-treatment and/or re-hospitalization. Switch therapy for LRTI was useful for the reduction of length of hospital stay without increasing risk of re-treatment and re-hospitalization in patients with SMID.


Assuntos
Antibacterianos/administração & dosagem , Infecções Comunitárias Adquiridas/tratamento farmacológico , Substituição de Medicamentos , Deficiência Intelectual/complicações , Transtornos das Habilidades Motoras/complicações , Infecções Respiratórias/tratamento farmacológico , Administração Oral , Adolescente , Adulto , Criança , Pré-Escolar , Infecções Comunitárias Adquiridas/complicações , Feminino , Humanos , Lactente , Infusões Intravenosas , Japão , Tempo de Internação/estatística & dados numéricos , Masculino , Infecções Respiratórias/complicações , Estudos Retrospectivos , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento
16.
Tohoku J Exp Med ; 246(3): 199-203, 2018 11.
Artigo em Inglês | MEDLINE | ID: mdl-30487373

RESUMO

Neonatal sepsis continues to be a global problem with significant morbidity and mortality, because of the difficulty in predicting its onset with clinical symptoms alone. Thus, the presence of biomarkers is useful for the diagnosis of neonatal sepsis. Presepsin is a 13-kDa truncated form of soluble CD14 that is produced through proteolytic cleavage on activated monocytes. Presepsin, consisting of 64 amino acid residues, has been proposed as a reliable biomarker for the early diagnosis of sepsis in neonates. However, some biomarkers for the diagnosis of sepsis are elevated during the early neonatal period due to physiological variation, whereas such variation in presepsin levels is uncertain. The objective of this study is to investigate the physiological variation in plasma presepsin levels during the early neonatal period. This prospective study included 30 full-term healthy neonates, including 15 neonates delivered by cesarean section. Plasma presepsin levels were examined at birth and on the first day and the fifth day of life in neonates, and the levels on the 5th day of life were lower than those at any other points (P < 0.001). Moreover, there was no significant difference of plasma presepsin levels between neonates delivered vaginally and by cesarean section. The physiological variation in plasma presepsin levels was observed during the early neonatal period. Attention needs to be paid when measuring plasma presespsin levels for the screening of sepsis during the early neonatal period.


Assuntos
Receptores de Lipopolissacarídeos/sangue , Fragmentos de Peptídeos/sangue , Biomarcadores/sangue , Proteína C-Reativa/metabolismo , Calcitonina/sangue , Demografia , Feminino , Humanos , Recém-Nascido , Contagem de Leucócitos , Masculino
18.
J Infect Chemother ; 23(10): 713-716, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28408303

RESUMO

We report an infant with hydrocephalus as the initial manifestation of Mycoplasma hominis-associated meningitis, who recovered without appropriate antimicrobial treatment. The analysis of the 16S rRNA gene by polymerase chain reaction amplification using universal primers and pathogen-specific primers was useful for the diagnosis and the investigation of serial detection status of the pathogen. This method may be helpful for the assessment of the frequency and the prediction of severity in M. hominis-associated central nervous system infection in infants, and investigating the association between M. hominis and the development of hydrocephalus.


Assuntos
Hidrocefalia/microbiologia , Meningite/microbiologia , Infecções por Mycoplasma/microbiologia , Mycoplasma hominis/patogenicidade , Humanos , Lactente , Masculino
19.
J Infect Dis ; 213(5): 848-55, 2016 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-26410591

RESUMO

BACKGROUND: The immune responses to pneumococcal conjugate vaccine (PCV) are low in immunocompromised hosts. The effect of memory B cells on the immune response to PCV remains elusive. METHODS: In this prospective study, 53 children who received 7-valent PCV were enrolled. Antipneumococcal immunoglobulin G (IgG) levels and opsonization index (OI) titers, along with lymphocyte subsets, were investigated in immunocompromised and immunocompetent hosts. Immunocompromised patients comprised 8 hematopoietic stem cell transplant recipients (group A) and 9 immunosuppressive therapy recipients (group B), and controls consisted of 14 children aged >1 year (group C) and 22 infants (group D). RESULTS: Serotype-specific IgG concentrations and OIs in group A were lower than those in group C. These did not differ among groups B, C, and D. The rates of achieving immunity (defined as an IgG level of 1.0 µg/mL and an OI of 8) in group A were also lower than in group C. Despite the sustained numbers of total T cells and B cells, CD27(+) B-cell and CD4(+) T-cell counts in group A were lower than those in group C. In group B, the immunoglobulin D-expressing CD27(-) B-cell count was only lower than that in group C. CONCLUSIONS: Circulating numbers of CD27(+) B cells, rather than CD4(+) T cells, may predict the effective PCV responses in immunocompromised children.


Assuntos
Linfócitos B/fisiologia , Vacina Pneumocócica Conjugada Heptavalente/imunologia , Infecções Pneumocócicas/prevenção & controle , Adolescente , Anticorpos Antibacterianos/sangue , Linfócitos T CD4-Positivos , Criança , Pré-Escolar , Humanos , Hospedeiro Imunocomprometido , Imunoglobulina G/sangue , Lactente , Membro 7 da Superfamília de Receptores de Fatores de Necrose Tumoral/metabolismo
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa